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Abstract
Background: Highly pathogenic influenza A/H5N1 has caused outbreaks in wild birds and poultry in Asia, Africa and Europe.
It has also infected people, especially children, causing severe illness and death. Although the virus shows limited ability to
transmit between humans, A/H5N1 represents a potential source of the next influenza pandemic. This study assesses the
safety and immunogenicity of aluminium hydroxide adjuvanted (Al) and non adjuvanted influenza A/Vietnam/1194/2004
NIBRG-14 (H5N1) vaccine in children.
Methods and Findings: In a Phase II, open, randomised, multicentre trial 180 children aged 6 months to 17 years received
two injections, 21 days apart, of vaccine containing either: 30 mg haemagglutinin (HA) with adjuvant (30 mg+Al) or 7.5 mg
HA without adjuvant. An additional 60 children aged 6–35 months received two ‘‘half dose’’ injections (ie 15 mg+Al or
3.8 mg). Safety was followed for 21 days after vaccination. Antibody responses were assessed 21 days after each injection
and cellular immune responses were explored. Vaccination appeared well tolerated in all age groups. The 30 mg+Al
formulation was more immunogenic than 7.5 mg in all age groups: in these two groups 79% and 46% had
haemagglutinination inhibition antibody titres $32 (1/dil). Among 6–35 month-olds, the full doses were more
immunogenic than their half dose equivalents. Vaccination induced a predominantly Th2 response against H5 HA.
Conclusions: This influenza A(H5N1) vaccine was well tolerated and immunogenic in children and infants, with Al adjuvant
providing a clear immunogenic advantage. These results demonstrate that an H5N1 Al-adjuvanted vaccine, previously
shown to be immunogenic and safe in adults, can also be used in children, the group most at risk for pandemic influenza.
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Introduction
The emergence of a novel influenza virus, against which the
bulk of the world’s population has no immunity, presents a
significant pandemic risk. Highly pathogenic avian influenza A/
H5N1 viruses have rapidly expanded their geographical range,
with infected birds identified across Asia, Africa, the Middle East
and Europe [1]. As of June 2008, 382 cases of human infection by
H5N1 had been confirmed, of which 46% (179 cases) were aged
0–19 years, and 63% (241 cases) were recorded as fatal [2].
Although current highly pathogenic H5N1 strains do not meet all
the criteria for a pandemic virus [3] since they appear poorly able
to spread from person-to-person, a probable case of human-to-
human transmission has been recorded [4]. Each case of human
infection by this subtype presents the potential for the virus to
acquire the ability to transmit more effectively from person-to-
person. Avian H5N1 therefore represents a potential source of the
next influenza pandemic [5]. It has been estimated that a severe
pandemic in the United States could infect 200 million people,
resulting in clinical illness in 90 million and death in 2 million [6].
The same study predicted that as a consequence of illness within
the working population, gross domestic product could decrease by
5% and the financial burden of providing outpatient care for 18 to
45 million people could total $675 billion.
During an influenza pandemic, children are expected to be
severely affected. Given reports of mortality rates of close to 90%
in children infected with avian A/H5N1 strains in Thailand, the
evaluation of human H5N1 vaccines in young people is therefore
crucial [7]. As well as being at high risk of contracting influenza,
children are key in viral transmission: they shed influenza virus
more efficiently and for longer than adults and tend to have
extensive social networks [8].
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4028Preparation for an influenza pandemic includes stock-piling of
antivirals and the development of candidate vaccines. Conven-
tional influenza vaccines may not be suitable against a pandemic
caused by influenza strain such as H5N1 due to the lack of pre-
existing immunity in the human population against any newly
emerged strain, and also the low immunogenicity of H5N1 strains
in particular [9]. Alternative methods for rapid production and
dose-reduction of vaccines are desirable since an immunologically
naı ¨ve population will require at least two doses of an H5N1
vaccine and the global response to an influenza pandemic will
require the maximum number of vaccine doses in the shortest
possible time after the onset of the pandemic[3,10–12].
The aim of the present study was to document in Thai children
the safety and immunogenicity of an H5N1 influenza vaccine
based on a reference strain derived by the UK National Institute
for Biological Standards and Control (NIBSC) from the patho-
genic influenza A Vietnam/1194/2004 strain. This vaccine has
been shown to be safe, immunogenic and able to induce cross-
reactive immune response in adult volunteers [13]. Here, we
present data from the first part (up to day 42) of a continuing trial.
This trial also explored the Th1/Th2 balance of cellular immune
responses before and after vaccination in infants and young
children.
Methods
This multicentre, randomised, open Phase II trial evaluated the
safety and humoral immunogenicity of different formulations of
influenza A/Vietnam/1194/2004 NIBRG-14 (H5N1) vaccine
and explored the cellular immune responses to the vaccine in
Thai children.
The study was conducted in accordance with all relevant
regulations and Good Clinical Practice (GCP) guidelines.
The study protocol was approved by the independent ethics
committees of Chulalongkorn Hospital and the Queen Sirikit
National Institute of Child Health (Children’s Hospital) prior to
the start of the trial. The clinical trial protocol and the supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Participants
Healthy children, aged 6 months to 17 years, were recruited at
two centres in Bangkok, Thailand between June and September
2007. The main exclusion criteria were: ongoing febrile illness;
recent receipt (preceding three months) of blood or blood-derived
products; seropositivity for Hepatitis B, C, or HIV; history of
H5N1 infection or previous vaccination with an avian influenza
vaccine; any vaccination during the previous four weeks, or
planned in the following four weeks; congenital or acquired
immunodeficiency; immunosuppressive therapy within the pre-
ceding six months; long-term systemic corticosteroid therapy;
systemic hypersensitivity to any of the vaccine components or a
history of life-threatening reaction to vaccines containing the same
substances; pregnancy; or chronic illness at a stage which could
interfere with trial conduct or completion.
Before enrolment, each child’s parents (or other legal represen-
tative) provided their written informed consent and each child
aged 7 years or older provided written informed assent.
Vaccine
The H5N1 vaccine was a monovalent A/H5N1, inactivated,
split virion-influenza virus vaccine (Sanofi Pasteur, Lyon, France).
It was propagated in embryonated hens’ eggs, using the licensed
manufacturing process for the interpandemic vaccine VaxigripH,
as described previously [13]. The vaccine strain was the influenza
A/Vietnam/1194/NIBRG-14 (H5N1) reference strain prepared
by the NIBSC, and is one of the reference viruses indicated as
suitable for use in a mock-up vaccine by the European Medicines
Agency (EMEA) [14].
Based on the results from a previous trial in French adults [13],
two formulations were selected for investigation in groups of
children of all ages: 30 mg HA with aluminium hydroxide adjuvant
(30 mg+Al), and 7.5 mg HA without adjuvant (7.5 mg). Further-
more, in a subgroup of the youngest age group (aged 6 to 35
months), two ‘‘half-dose’’ formulations were evaluated, i.e.,
15 mg+Al and 3.75 mg.
Vaccine was presented in ready-to-use multi-dose vials. Adju-
vanted vaccine vials contained per millilitre, 60 mg HA and 1200 mg
aluminium hydroxide adjuvant, expressed as Al
3+.T h ev o l u m eo f
vaccine withdrawn for injection of the full or half doses was
respectively, 0.5 ml or 0.25 ml. Non-adjuvanted vaccine vials
contained 12.5 mg HA/ml, and 0.6 or 0.3 ml were withdrawn for
injection.
Procedures
As a precaution, children were enrolled and vaccinated in an
age-based step-down design. In the first step, 60 children aged 9–
17 years were enrolled and randomised to receive one of the two
full-dose formulations. Safety data from the first seven days after
the first vaccination were reviewed before deciding whether to
proceed to the second vaccination of these first 60 children, and to
enrol and vaccinate the next 60 children, aged 3–8 years. The
same procedure was followed before enrolling and vaccinating 60
children aged 6–35 months with the half dose vaccines, and again
before enrolling and vaccinating the final 60 children aged 6–35
months with the full dose vaccines. The randomisation list was
generated by the sponsor’s biostatistics department using the block
permutation method, stratified by age group and centre.
Randomization lists for each age group and centre featured a
list of sequentially assigned subject number and, concealed
underneath a scratchable patch, the corresponding vaccine
assigned assigned to that subject number. At each centre, the
enrolling investigator enrolled the subject, assigned the next non-
assigned subject number on the list, then scratched the patch to
reveal the assigned treatment group.
All subjects received two intramuscular injections, 21 days
apart, of the assigned formulation in the deltoid (children aged
$12 months) or anterolateral aspect of the thigh (,12 months)
and were kept under observation for 30 minutes each time. Blood
samples, collected before and 21 days after vaccination, were
processed at the trial centres and serum samples were stored and
shipped frozen at 217uC to the Global Clinical Immunology
Laboratory (sanofi pasteur, Pennsylvania, USA) for analysis.
Additional blood samples were collected in sodium heparin tubes
before the first vaccination, and 8 days after the second
vaccination from the 120 children aged 6–35 months and
peripheral blood mononuclear cells were isolated for cellular
immune response testing.
Safety analysis
Parents were given safety diaries, thermometers and rulers to
record any adverse events occurring up to day 21 after vaccination.
The daily occurrence of a set of solicited systemic and injection site
reactions were recorded up to day 7 following vaccination (see
results for details). The severity of non-measurable reactions was
assessed using a grading scale of 1 to 3. During the following visit,
investigators interviewed the children and their parents, transcribed
events into case report forms, and assessed whether they were
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suitable for infants, and therefore differed between children ,2
years old and older children (see results for details).
Antibody response
Serum samples were tested for their ability to inhibit
haemagglutination and to neutralise influenza A/H5N1 virus.
The haemagglutination inhibition assay reflects the ability of
specific anti-influenza antibodies to inhibit haemagglutination of
horse red blood cells by influenza virus HA, and has been
described previously [13]. The starting dilution of the HI assay
used here was 1:8, and seroresponse threshold was 1:32. Titres
were expressed as the reciprocal of dilution (1/dil). Samples
without detectable antibody activity were assigned the titre of half
the assay detection limit, i.e. a titre of 1:4.
Neutralising antibody activity was measured using a seroneu-
tralisation (SN) assay based on the ability of antibodies to inhibit
the infection of Madin-Darby canine kidney (MDCK) cell culture
by influenza virus. Inactivated human serum samples were pre-
incubated with a standardised amount of virus prior to the
addition of MDCK cells. After overnight incubation, enzyme-
linked immunosorbent assay (ELISA) was used to measure the
viral nucleoprotein in infected MDCK cells. Since serum
antibodies to the influenza virus HA inhibit the viral infection of
MDCK cells, the optical density results of the ELISA were
inversely proportional to the serum Ab concentration. Samples
without detectable antibody activity were assigned the titre of half
the assay’s detection limit (10), i.e. a titre of 5.
Cell Mediated Immunity
Th1 and Th2 cytokine secretion was assessed on freshly isolated
peripheral blood mononuclear cells (PMBCs) after 4 days of in
vitro re-stimulation with recombinant haemagglutinin (rHA)
analogous to that of Influenza A/Vietnam/1203/2004(H5N1)
(Protein Science Corporation, Meriden, CT) or A/New Caledo-
nia/20/99(H1N1) split inactivated vaccine. Cytokine secretion
(interleukin (IL) 5 and IL13 as surrogate markers of a Th2
response, and interferon gamma (IFNc), and tumor necrosis factor
alpha (TNFa) as markers of a Th1 response) was quantified in the
cell supernatant by Luminex technology. Briefly, PBMCs were
stimulated in vitro in 96-well plate with 0.1 mg/ml of rHA.
Secreted cytokines were measured by Luminex using Human
cytokine 4-plex and Bio-Plex reagent kits (Bio-Rad, Hercules, CA)
according to the manufacturer’s instruction. Premixed anti-
cytokine biotinylated antibody capture beads were dispensed in
a pre-moistened filter plate. The beads were washed standard,
control and samples were dispensed into the plate. After
30 minutes at room temperature, cells were washed before
biotinylated detection antibody solution was added to each well.
Plates were incubated for a further 30 minutes as above. After
several washes, streptavidin-PE were dispensed into each well of
the plate and incubated as above for 10 more minutes. Data were
acquired with the Bio-plex Luminex 100 (Bio-Rad, Hercules, CA)
then analyzed with the Bio-plex manager software.
Statistical Analysis
The study cohort (N=240) provided a probability .90% of
detecting an adverse event with an incidence of 1% in the study,
and a probability of 70% for each pooled adjuvanted and non-
adjuvanted group (N=120). Statistical analyses were descriptive
with no hypothesis testing, and were performed on the full analysis
set. In line with EMEA immunogenicity criteria [14,15], HI titres
were described per group using i) geometric mean titre (GMT) at
each timepoint, ii) the geometric mean ratio of titres between pre-
and post-vaccination (GMTR), iii) the proportion of subjects with
titres $32, and, referred to hereafter as the seroresponse rate iv)
the proportion of subjects with either a pre-vaccination titre of ,8
and a post-vaccination titre of $32, or a 4-fold rise in titre from a
pre-vaccination titre of $8, referred to as hereafter as the
seroconversion rate. In a population that is naı ¨ve before
vaccination, the above defined seroresponse and seroconversion
rates are identical, and the GMTR is equal the GMT divided by
the half the assay’s lower detection limit (i.e., 4). Neutralising titres
were described per group as GMT and as the proportion of each
group with 2- or 4-rise in titre after vaccination. Analyses of cell
mediated responses were descriptive.
Results
Between June and September 2007, 240 healthy children, aged
between 6 months and 17 years, were recruited and vaccinated as
planned. Of these, 239 successfully completed the trial, and one
subject in the 3–8 year, 7.5 mg group was withdrawn at the Day
21 visit, before the second vaccination, for non-compliance with
the protocol. All available data were included in the analyses, i.e.,
data on 240 subjects for the first vaccination, and 239 for the
second vaccination. Table 1 shows the age and gender
distribution within each age group; 47.9% of the overall
population was male.
Table 1. Age and sex distribution across groups.
Age and vaccine formulation group: dose and adjuvant content
9 to 17 years 3 to 8 years 6 to 35 months
30 mg+Al 7.5 mg3 0 mg+Al 7.5 mg3 0 mg+Al 15 mg+Al 7.5 mg3 . 8 mg
N randomized at day 0 30 30 30 30 30 30 30 30
Age in years
Mean (standard deviation) 12.7 (2.6) 12.3 (2.2) 6.5 (1.9) 5.8 (1.8) 1.6 (0.6) 2.0 (0.8) 1.7 (0.7) 1.8 (0.8)
[Min; Max] 9.0; 17.3 9.1; 16.8 3.0; 8.7 3.0; 8.9 0.5; 3.0 0.5; 3.0 0.6; 3.0 0.5; 2.9
Gender n (%)
Male 14 (47) 18 (60) 14 (47) 16 (53) 14 (47) 14 (47) 12 (40) 13 (43)
Female 16 (53) 12 (40) 16 (53) 14 (47) 16 (53) 16 (53) 18 (60) 17 (57)
doi:10.1371/journal.pone.0004028.t001
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age and vaccine group experiencing each solicited reaction at least once during period Day 0–7.
6 to 35 months
30 mg+Al 7.5 mg1 5 mg+Al 3.8 mg
n/N (%) n/N (%) n/N (%) n/N (%)
Injection site reactions*
Tenderness (6–23 months only) 10/23 (44%) 8/24 (33%) 4/14 (29%) 3/15 (20%)
Pain (24–35 months only) 2/7 (29%) 1/6 (17%) 7/16 (44%) 9/15 (60%)
Ecchymosis (24–35 months only)
{ 0/7 2/6 (33%) 1/16 (6%) 2/15 (13%)
Erythema (6–35 months)
{ 5/30 (17%) 6/30 (20%) 8/30 (27%) 5/30 (17%)
Swelling (6–35 months)
{ 2/30 (7%) 3/30 (10%) 3/30 (10%) 2/30 (7%)
Induration (6–35 months)
{ 0/30 3/30 (10%) 4/30 (13%) 3/30 (10%)
Systemic reactions*
Fever (6–35 months){ 4/30 (13%) 5/30 (17%) 7/30 (23%) 4/30 (13%)
Headache (24–35 months only) 1/7 (14%) 0/6 2/16 (13%) 4/15 (27%)
Malaise (24–35 months only) 2/7 (29%) 2/6 (33%) 3/16 (19%) 5/15 (33%)
Myalgia (24–35 months only) 1/7 (14%) 0/6 2/16 (13%) 5/15 (33%)
Shivering (24–35 months only) 0/7 0/6 0/16 2/15 (13%)
Vomiting (6–23 months only) 7/23 (30%) 7/24 (29%) 1/14 (7%) 0/15
Abnormal crying (6–23 months only) 4/23 (17%) 8/24 (33%) 7/14 (50%) 1/15 (7%)
Drowsiness (6–23 months only) 4/23 (17%) 4/24 (17%) 2/14 (14%) 0/15
Loss of appetite (6–23 months only) 5/23 (22%) 8/24 (33%) 4/14 (29%) 2/15 (13%)
Irritability (6–23 months only) 7/23 (30%) 10/24 (42%) 5/14 (36%) 2/15 (13%)
*Injection site tenderness, vomiting, abnormal crying, drowsiness and loss of appetite were solicited only for children younger than 24 months; injection site pain, or
ecchymosis, headache, malaise, myalgia and shivering were solicited only for children older than 24 months. Other injection site reactions were solicited for all children.
{any measurable reaction .0c m .
{oral temperature $37.4uC.
N is the number of participants for whom each reaction was solicited, and for whom data are available.
doi:10.1371/journal.pone.0004028.t003
Table 2. Reactogenicity within 7 days after first vaccination in children aged 3–17 years: number and proportion subjects per age
and vaccine group experiencing each solicited reaction at least once during period Day 0–7.
9 to 17 years 3 to 8 years
30 mg+Al (N=30) 7.5 mg (N=30) 30 mg+Al (N=30) 7.5 mg (N=30)
n( % ) n( % ) n( % ) n( % )
Injection site reactions
Pain 12 (40%) 11 (37%) 19 (63%) 11 (37%)
Ecchymosis* 0 0 1 (3%) 0
Erythema* 7 (23%) 6 (20%) 1 (3%) 2 (7%)
Swelling* 1 (3%) 0 1 (3%) 1 (3%)
Induration* 0 1 (3%) 3 (10%) 1 (3%)
Systemic reactions
Fever{ 2 (7%) 2 (7%) 3 (10%) 5 (17%)
Headache 3 (10%) 6 (20%) 5 (17%) 5 (17%)
Malaise 1 (3%) 2 (7%) 3 (10%) 8 (27%)
Myalgia 3 (10%) 5 (17%) 12 (40%) 4 (13%)
Shivering 0 2 (7%) 0 1 (3%)
*any measurable reaction .0c m .
{oral temperature $37.4uC.
N is the number of participants for whom each reaction was solicited, and for whom data are available.
doi:10.1371/journal.pone.0004028.t002
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All tested formulations of the A/H5N1 vaccine appeared well
tolerated in all age groups over the 42 day period of observation.
There were no vaccine related serious adverse events, no other
significant adverse events and only two subjects experienced an
unsolicited adverse event judged to be vaccine related: one subject
had a maculo-papular rash which spontaneously disappeared after
one day, and one subject had an injection site papule and mild
itching which spontaneously resolved after 2 days. Both subjects
were 2 year-olds and had received the 15 mg+Al formulation.
These adverse events were not immediate, they were of short
duration and no action was taken. Only five solicited systemic
reactions were classed as severity grade 3 (one case each of
headache, irritability, lost appetite, vomiting, and fever, all of
which occurred with the non-adjuvanted vaccine in children
younger than 3 years).
Combining data from children of all three age groups, the
proportion experiencing at least one solicited injection site reaction
in the seven days following the first injection of the 30 mg+Al
vaccine was 57% (N=90, 95% confidence interval: 46–67), and
was 44% (95% CI: 34–55) following the first injection of 7.5 mg.
The proportion experiencing solicited systemic reactions after the
first injection was the same with each of these two formulations:
44% (95% CI: 34–55). Although sample sizes per group were too
small to draw conclusions, no differences in vaccine reactogenicity
were apparent between any of the age or vaccine formulation
groups (Tables 2 and 3). Reactogenicity was no higher after the
second injection, and indeed appeared to be lower than after the
first: the overall incidences of solicited injection site reactions in the
seven days after the second injection of 30 mg+Al and 7.5 mg were
47% (95% CI: 36–58) and 40% (95% CI: 30–51), and the
corresponding incidences of solicited systemic reactions were 39%
(95% CI: 29–50) and 34% (95% CI: 24–45). This trend for fewer
reactions after the second injection was observed in all age and
vaccine formulation subgroups (data not shown).
Fever, the only consistently evaluated and objectively measur-
able solicited systemic reaction, affected between 2 and 7 children
per group of 30 after the first injection and between 0 and 8 after
the second, and tended to occur more frequently among younger
children.
Haemagglutination inhibition antibody response
Before vaccination, none of the subjects had detectable HI
antibodies to H5N1. The first vaccination induced an HI response
in at least one subject in each group of 30 children, but titres
remained low: the GMT 21 days after the first vaccination ranged
from 4.29 (95% CI: 3.8–4.83) to 8.48 (95% CI: 5.34–13.5) per
group. After the second vaccination, titres increased in all groups:
GMTs ranged from 16.4 (95% CI: 11.7; 22.8) and 60.4 (95% CI:
44.6; 81.9), and the seroresponse rate (number of subjects with
titres $32) ranged between 30% and 77% (Figure 1). Combining
all age groups, GMTs were higher after two injections of 30 mg+Al
than after two injections of 7.5 mg: 46.9 (95% CI: 38.6; 56.8),
compared with 21.5 (95% CI: 17.1;27.0). The corresponding
GMTRs between D0 and D42 were 11.7 and 5.44. Seroresponse
rates were also higher: 79% (95% CI: 69.0; 86.8) compared with
46% (95% CI: 35.4; 57.0). These higher responses with the
30 mg+Al formulation were observed consistently in all age groups
(Figure 1). In the youngest age group, half dose formulations
appeared to be slightly less immunogenic than their full dose
equivalents, but 95% confidence intervals were largely overlap-
ping. Finally, there was no effect of age on the HI immune
response.
Neutralising antibody responses
Neutralising Ab responses followed a similar pattern to those of
HI. The highest proportion ($90%) of individuals in each age
group displaying a four-fold or greater rise in titre between day 0
and 42 was observed after two injections of the 30 mg+Al vaccine,
as were the highest GMTs (Table 4).
Figure 1. Haemagglutination inhibition antibody response 21 days after two injections, 21 days apart of adjuvanted or non-
adjuvanted H5N1 vaccine. Results are presented per age and vaccine formulation group as geometric mean titres (GMT) and the proportion of
subjects with titres $32.
doi:10.1371/journal.pone.0004028.g001
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Before vaccination of these 6–35 month olds, an H1N1-specific
response (data not shown) and a weak cross-reactive CD4 response
against H5 (Figure 2) were detected, with both Th1 (IFNc) and
Th2 (IL13) cytokine secretion. This response was mainly directed
against epitopes included in the H1N1 vaccine strain. More than
50% subjects were negative for H1N1 epitopes and only a low
reactivity was found against the recombinant HA antigen in 8/112
subjects for IFN-c and 26/114 subjects for IL13.
Eight days after the second vaccination, concentrations of both
Th1 (IFNc) and Th2 (IL-5 and IL-13) cytokines increased in all
study groups, with a predominant secretion of IL13, even in
absence of aluminium adjuvant (figure 2). Vaccination did not
significantly increase TNFa secretion and induced a predomi-
nantly Th2 response against rHA, as reflected by the weak IFNc/
IL13 ratios of between 0.077 (95%CI: 0.041–0.145) in the 7.5 mg
group and 0.211 (0.118–0.376) in the 3.75 mg grroup.
Discussion
Children and young adults are likely to be particularly
vulnerable to infection during an influenza pandemic and an
important source of infection for others. Some 40% of cases have
been predicted to occur in individuals aged 19 years or younger
[16]. Among human cases of highly pathogenic avian influenza A/
H5N1 virus infection confirmed over the last decade, a
disproportionately high number have been children, although this
is possibly due, in part, to the proximity between children and
poultry in areas of Asia where most of these cases have occurred
[17]. A recent study profiled the social contact networks of school
age children and teenagers in the USA as a way of assessing the
potential for influenza transmission within this population [8]. The
authors suggested that high school students are likely to form the
local transmission backbone for the next influenza pandemic.
Vaccination of children will therefore form an essential element
of pandemic influenza vaccination programs. Our study was
designed to evaluate the safety and immunogenicity of different
formulations of an A/H5N1 vaccine in children. The two full-dose
formulations chosen for this study and tested in all age groups of
children (theadjuvanted 30 mg formulationand the non-adjuvanted
7.5 mg formulation), had previously been evaluated in a trial in
French adults, and found to be well tolerated, immunogenic and
able to induce cross-reactive antibodies[13]. The two half-dose
formulationsevaluatedintheyoungest groupof children (aged 6–35
months) were chosen in line with recommendations for seasonal
influenza vaccination of young children [18], for whom a half of the
standard adult vaccine dose can be used. All formulations of the
H5N1 vaccine appeared to be well tolerated with notably no
evidence of increased reactogenicity after the second vaccination,
no seriousor significant adverse events and very fewseverity grade 3
solicited reactions. There were no marked differences in reactoge-
nicity between the higher-dose adjuvanted groups and the lower
dose non-adjuvanted groups. In accordance with published data
with licensed seasonal influenza, the youngest group of children
tended to have a higher incidence of fever [19].
It has been argued that due to the existence of numerous
undetected mild or asymptomatic cases [20], the true human case
fatality rate influenza A (H5N1) isconsiderablylower than the ,60%
calculated based only on confirmed cases reported by the WHO [2].
Indeed around 10% of a cohort of Hong Kong poultry workers had
a n t i - H 5a n t i b o d i e sa f t e rt h e1 9 9 7o u t b r e a ko fH 5 N 1[ 2 1 ] .T h e
children enrolled to our study in Bangkok showed no evidence of
having been previously exposed to H5N1 influenza. They had no
detectable antibody responses before vaccination, and the low levels
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PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e4028of immune response seen after the first vaccination are concordant
with a primary immune response, rather than a booster response.
The H5N1-specific CD4 responses seen in some 6–35 month-old
childrenislikelytobe dueto cross reactive T-cellresponses stimulated
by prior infection by other influenza strains. Such cross-reactive
cellular responses between influenza strains have been described
previously [22–24].
Antibody responses increased in all groups after the second
vaccination. In terms of both geometric mean titres and the HI
seroresponse rate, responses were highest among children vacci-
nated with the adjuvanted 30 mg formulation. Antibody responses
to both the adjuvanted 30 mg formulation and the non-adjuvanted
7.5 mg formulation appeared to be at least as good as, if not better
than those observed with the same vaccine formulations in a
Figure 2. Levels of IFNc and IL5 secreted after in vitro re-stimulation with recombinant H5 haemagglutinin by cells obtained before
and eight days after two injections, 21 days apart, of adjuvanted or non-adjuvanted H5N1 vaccine in groups of children aged 6–35
months. Symbols represent results from individual samples, bars indicate the median level.
doi:10.1371/journal.pone.0004028.g002
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PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e4028previous study in adults [13]. It should be pointed out that vaccines
in this study were presented in ready-to-use multi-dose vials,
whereas in the adult study, vaccines were presented as single dose
vials of vaccine and adjuvant for extemporaneous preparation. Both
assays used to document the antibody response are functional
assays, nevertheless, in absence of an established correlate of
protection, it is unclear how the haemagglutination inhibiting and
neutralising antibody responses documented in this study would
translate to efficacy against infection or disease in a pandemic
context. In their guidance for the licensing of pandemic vaccines,
the EMEA acknowledges this uncertainty and requires that mock
up vaccines be at least able to meet the three criteria defined for the
vaccinationofadultsorelderlyadultsagainst seasonalinfluenza;i.e.,
a GMTR of at least 2.5 or 2.0, a seroprotection rate of at least 70 or
60% and a seroconversion or significant titre increase rate of at least
40 or 30% [14,15]. Although in our study, the seroresponse
threshold considered was 1:32 instead of the 1:40 in the EMEA
criteria, with a GMTR of 11.7 and a seroresponse and
seroconversion rate of 79%, the 30 mg+Al formulation in children
in this study satisfy all three criteria.
Immune responses to the non-adjuvanted vaccines in Thai
children in our study appeared comparable to or higher than those
observed in a study among US children, despite a 6–12-fold
difference in the amount of antigen: after two doses of 45 mgH A
without adjuvant, the 38% had titres .1:40 [25]. Several factors
potentially contribute to this difference, including genetic factors, and
the lack of standardization of assay methods between laboratories.
We explored the Th1 and Th2 cytokine secretion profile in
subjects before and after vaccination. These analyses were
performed in the youngest group of children (6–35 months) as it
is in immunologically immature infants that immune responses are
most biased towards a Th2 response [26–28]. As expected, we
observed low levels of cytokine secretion with a Th2-dominant
profile before vaccination. In all groups, vaccination induced a
Th2-biased response to the H5 protein. Although the study design
did not allow the adjuvant effect to be separated from any antigen
dose effect, there was no evidence of increased Th2-dominance in
among subjects vaccinated with an adjuvanted vaccine.
In summary, these influenza A/H5N1 vaccines appeared
immunogenic and well tolerated in a population of naı ¨ve children
and infants from the age of 6 months, with the 30 mg+Al vaccine
formulation eliciting the greatest immune responses, at least as good
as those previously seen with the same vaccine formulation in adults.
Given the likely burden of disease in children and their role in disease
transmission, the vaccination of children will form an essential part of
pandemic vaccination campaigns to control the spread of the disease.
Furthermore, as the logistics of vaccine administration during a
pandemic are expected to be particularly challenging, the ability to
use the same vaccine across age groups will be a major advantage.
Supporting Information
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0004028.s001 (1.12 MB
PDF)
Checklist S1 CONSORT checklist
Found at: doi:10.1371/journal.pone.0004028.s002 (0.06 MB
DOC)
Acknowledgments
We are grateful to Dr Wanla Kulwichit, Faculty of Medicine,
Chulalongkorn University in Bangkok for sample preparation and cell
stimulation, the participating clinicians at each study site. We are also
grateful to the project team at sanofi pasteur for diligence and support, in
particular to Josef Weigel, Vincent Canouet and his team for trial set-up
and coordination, Christophe Carre ´ for statistical analysis, Drs Melanie
Saville and Peter Tsang for medical monitoring during the trial, and to
Grenville Marsh for his assistance in preparing the manuscript. We also
thank the study volunteers.
Author Contributions
Conceived and designed the experiments: SP NN. Performed the
experiments: TC UT CP NN. Analyzed the data: SP NN. Wrote the
paper: SP NN. Coordinating Investigator: TC UT CP. Contributed to the
interpretation of data and reviewed the draft article and approved the final
article: TC UT CP.
References
1. WHO, Areas reporting confirmed occurrence of H5N1 avian influenza in
poultry and wild birds since 2003, status as of 14.04.2008, http://gamapserver.
who.int/mapLibrary/Files/Maps/Global_SubNat_H5N1inAnimalConfirmed-
CUMULATIVE_20080414.png (accessed 4th May 2008).
2. WHO, Cumulative number of confirmed human cases of avian influenza A/
(H5N1) reported to WHO, http://www.who.int/csr/disease/avian_influenza/
country/cases_table_2008_04_30/en/index.html (accessed 4th May 2008).
3. Poland G (2006) Vaccines against avian influenza–a race against time.
N Engl J Med 354: 1411–13.
4. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, et al. (2005)
Probable person-to-person transmission of avian influenza A (H5N1).
N Engl J Med 352: 333–40.
5. WHO, The World Health Organization Global Influenza Program Surveillance
Network, Evolution of H5N1 avian influenza viruses in Asia (2005) Emerg Infect
Dis 11: 1515–21.
6. Congressional Budget Office. A potential influenza pandemic: possible
macroeconomic effects and policy issues. 8th December, 2005. (accessed 8th
May 2008, at http://www.dhhs.state.nh.us/DHHS/CDCS/LIBRARY/
Research/avian-cbo-economy.htm.).
7. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. (2005) Avian
influenza A (H5N1) infection in humans. N Engl J Med 353: 1374–
85.
8. Glass LM, Glass RJ (2008) Social contact networks for the spread of pandemic
influenza in children and teenagers. BMC Public Health 8: 61.
9. Wood JM (2002) Selection of influenza vaccine strains and developing pandemic
vaccines. Vaccine 20 (suppl 5): B40–44.
10. Schwartz B, Gellin B (2005) Vaccination strategies for an influenza pandemic.
J Infect Dis 191: 1210–5.
11. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM (2004)
Confronting the avian influenza threat: vaccine development for a potential
pandemic. Lancet Infect Dis 4: 499–509.
12. Webby RJ, Webster RG (2003) Are we ready for pandemic influenza? Science
302: 1519–22.
13. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, et al. (2006) Safety and
immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004
(H5N1) vaccine: phase I randomised trial. Lancet 367: 1657–64.
14. European Committee for Proprietary Medicinal Products. Guideline on dossier
structure and content for pandemic influenza vaccine marketing authorisation
application (CPMP/VEG/4717/03). European Agency for the Evaluation of
Medicinal Products, 5th April 2004. (accessed 8th May 2008 at www.emea.
europa.eu/pdfs/human/vwp/471703en.pdf).
15. European Committee for Proprietary Medicinal Products. Note for guidance on
harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96).
European Agency for the Evaluation of Medicinal Products, 12th March 1996.
(accessed 8th May 2008 at http://www.emea.europa.eu/pdfs/human/bwp/
021496en.pdf).
16. MeltzerMI,CoxNJ,FukudaK(1999)Theeconomicimpactof pandemicinfluenza
in the United States: priorities for intervention. Emerg Infect Dis 5: 659–71.
17. World Health Organization. Epidemiology of WHO-confirmed human cases of
avian influenza A(H5N1) infection Weekly epidemiological record 2006, 81,
249–260. http://www.who.int/wer/wer8126.pdf.
18. Committee on Infectious Diseases (2007) Prevention of Influenza: recommen-
dation for influenza immunisation of children, 2006–2007. Pediatrics 119:
846–851.
19. Delore V, Salamand C, Marsh G, Arnoux S, Pepin-Covatta S, et al. (2006)
Long-term Clinical Trial Safety Experience with the Inactivated Split Influenza
Vaccine, VaxigripH. Vaccine 24: 1586–1592.
20. Li FC, Choi BC, Sly T, Pak AW (2008) Finding the real case-fatality rate of
H5N1 avian influenza. J Epidemiol Community Health 62: 555–9.
21. Bridges CB, Lim W, Hu-Primmer J, Sims L, Fukuda K, et al. (2002) Risk of
influenza A (H5N1) infection among poultry workers, Hong Kong, 1997–1998.
J Infect Dis 185: 1005–10.
H5N1 Vaccine in Thai children
PLoS ONE | www.plosone.org 8 December 2008 | Volume 3 | Issue 12 | e402822. Zeman AM, Holmes TH, Stamatis S, Tu W, He XS, et al. (2007) Humoral and
cellular immune responses in children given annual immunization with trivalent
inactivated influenza vaccine. Pediatr Infect Dis J 26: 107–15.
23. He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM,
Greenberg HB (2008) Phenotypic changes in influenza-specific CD8+ T cells
after immunization of children and adults with influenza vaccines. J Infect Dis
197: 803–11.
24. van Riet E, Adegnika AA, Retra K, Vieira R, Tielens AG, et al. (2007) Cellular
and humoral responses to influenza in gabonese children living in rural and
semi-urban areas. J Infect Dis 196: 1671–8.
25. World Health Organization. Tables on the Clinical trials of pandemic influenza
prototype vaccines. Accessed 25 June 2008, at: http://www.who.int/vaccine_
research/diseases/influenza/flu_trials_tables/en/index3.html.
26. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, et al. (1996) Neonatal
and early life immune responses to various forms of vaccine antigens
qualitatively differ from adult responses: predominance of a Th2-biased pattern
which persists after adult boosting. Eur J Immunol 26: 1489–96.
27. Delespesse G, Yang LP, Ohshima Y, Demeure C, Shu U, et al. (1998)
Maturation of human neonatal CD4+ and CD8+ T lymphocytes into Th1/Th2
effectors. Vaccine 16: 1415–9.
28. Siegrist CA (2001) Neonatal and early life vaccinology. Vaccine 19: 3331–46.
H5N1 Vaccine in Thai children
PLoS ONE | www.plosone.org 9 December 2008 | Volume 3 | Issue 12 | e4028